FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Meir Bialer

Research Profile

Chemicals & Drugs

Disorders

Living Beings

Concepts & Ideas

Procedures

Physiology

Drug Interactions

Co-author Network

Publications

TOP 3
Hiren R Modi; Ameer Y Taha; Mireille Basselin; Meir Bialer; Rosalind A Coleman; Lei O Li; Stanley I Rapoport
Propylisopropylacetic acid (PIA), a constitutional isomer of valproic acid, uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: a potential drug for bipolar disorder.
Meir Bialer; Svein I Johannessen; René H Levy; Emilio Perucca; Torbjörn Tomson; H Steve White
Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI).
Meir Bialer
How did phenobarbital's chemical structure affect the development of subsequent antiepileptic drugs (AEDs)?

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Meir Bialer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Hiren R Modi; Ameer Y Taha; Mireille Basselin; Meir Bialer; Rosalind A Coleman; Lei O Li; Stanley I Rapoport
Propylisopropylacetic acid (PIA), a constitutional isomer of valproic acid, uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: a potential drug for bipolar disorder.
Biochimica et biophysica acta 2013;1831(4):880-6.
2013: Meir Bialer; Svein I Johannessen; René H Levy; Emilio Perucca; Torbjörn Tomson; H Steve White
Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI).
Epilepsy research 2013;103(1):2-30.
2012: Meir Bialer
How did phenobarbital's chemical structure affect the development of subsequent antiepileptic drugs (AEDs)?
Epilepsia 2012;53 Suppl 8():3-11.
2012: Meir Bialer; Phil E M Smith
Special issue: Phenobarbital: the Centenary - 10th European Congress on Epileptology, London - October 1, 2012. Introduction.
Epilepsia 2012;53 Suppl 8():1-2.
2012: Meir Bialer
Why are antiepileptic drugs used for nonepileptic conditions?
Epilepsia 2012;53 Suppl 7():26-33.
2012: Phil Smith; Meir Bialer
The borderland of epilepsy: Chairs' Symposium, 10th European Congress on Epileptology, London--October 1, 2012. Introduction.
Epilepsia 2012;53 Suppl 7():1-2.
2012: Meir Bialer
Comments on the working group's 2012 review of the Program.
Epilepsia 2012;53(10):1844-6.
2012: Meir Bialer
Chemical properties of antiepileptic drugs (AEDs).
Advanced drug delivery reviews 2012;64(10):887-95.
2012: Meir Bialer; Patricio Soares-da-Silva
Pharmacokinetics and drug interactions of eslicarbazepine acetate.
Epilepsia 2012;53(6):935-46.
2012: Idit Bejarano-Achache; Meir Bialer; Liran Levy; Liat Mlynarsky; Mordechai Muszkat; Yoseph Caraco
Effects of CYP4F2 polymorphism on response to warfarin during induction phase: a prospective, open-label, observational cohort study.
Clinical therapeutics 2012;34(4):811-23.
2012: Naama Hen; Meir Bialer; Boris Yagen
Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates.
Journal of medicinal chemistry 2012;55(6):2835-45.
2012: Tawfeeq Shekh-Ahmad; Meir Bialer; Eylon Yavin
Synthesis and anticonvulsant evaluation of dimethylethanolamine analogues of valproic acid and its tetramethylcyclopropyl analogue.
Epilepsy research 2012;98(2-3):238-46.
2012: H Steve White; Karen S Wilcox; Boris Yagen; Anitha B Alex; Naama Hen; Dan Kaufmann; John H McDonough; Amanda Pollock; Tawfeeq Shekh-Ahmad; James P Stables; Meir Bialer
A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage.
Epilepsia 2012;53(1):134-46.
2011: Neta Pessah; Jakob Shimshoni; Bogdan Wlodarczyk; Boris Yagen; Richard H Finnell; Naama Hen; Meir Bialer
Design and pharmacological activity of glycinamide and N-methoxy amide derivatives of analogs and constitutional isomers of valproic acid.
Epilepsy & behavior : E&B 2011;22(3):461-8.
2011: Lawrence J Lambrecht; Tawfeeq Shekh-Ahmad; Wesley M Todd; Mark B Halvorsen; Meir Bialer
Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate.
Epilepsia 2011;52(10):1877-83.
2011: Naama Hen; Meir Bialer; Boris Yagen; Alfonso Maresca; Mayank Aggarwal; Arthur H Robbins; Robert McKenna; Andrea Scozzafava; Claudiu T Supuran
Anticonvulsant 4-aminobenzenesulfonamide derivatives with branched-alkylamide moieties: X-ray crystallography and inhibition studies of human carbonic anhydrase isoforms I, II, VII, and XIV.
Journal of medicinal chemistry 2011;54(11):3977-81.
2010: Meir Bialer; Svein I Johannessen; René H Levy; Emilio Perucca; Torbjörn Tomson; H Steve White
Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X).
Epilepsy research 2010;92(2-3):89-124.
2010: Neta Pessah; Dan Kaufmann; Boris Yagen; Naama Hen; Bogdan Wlodarczyk; Richard H Finnell; Meir Bialer
Comparative pharmacodynamic and pharmacokinetic analysis of two anticonvulsant halo derivatives of 2,2,3,3-tetramethylcyclopropanecarboxamide, an amide of a cyclic analog of valproic acid.
Epilepsia 2010;51(10):1944-53.
2010: Meir Bialer; Kamal K Midha
Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability.
Epilepsia 2010;51(6):941-50.
2010: Dan Kaufmann; Boris Yagen; Anne Minert; Bogdan Wlodarczyk; Richard H Finnell; Volker Schurig; Marshall Devor; Meir Bialer
Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid.
Neuropharmacology 2010;58(8):1228-36.
2010: Naama Hen; Meir Bialer; Bogdan Wlodarczyk; Richard H Finnell; Boris Yagen
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
Journal of medicinal chemistry 2010;53(10):4177-86.
2010: Jakob A Shimshoni; Boris Yagen; Bogdan Wlodarczyk; Richard H Finnell; Volker Schurig; Meir Bialer
Evaluation of stereoselective anticonvulsant, teratogenic, and pharmacokinetic profile of valnoctylurea (capuride): a chiral stereoisomer of valproic acid urea derivative.
Epilepsia 2010;51(3):323-32.
2010: Meir Bialer; H White
Key factors in the discovery and development of new antiepileptic drugs.
Nature reviews. Drug discovery 2010;9(1):68-82.
2009: Meir Bialer
Pharmacodynamic and pharmacokinetic characteristics of intravenous drugs in status epilepticus.
Epilepsia 2009;50 Suppl 12():44-8.
2009: Dan Kaufmann; Meir Bialer; Jakob Shimshoni; Marshall Devor; Boris Yagen
Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues.
Journal of medicinal chemistry 2009;52(22):7236-48.
2009: Akinobu Okada; Hiroko Noyori; Boris Yagen; Jakob Avi Shimshoni; Meir Bialer; Michio Fujiwara
Anticonvulsant profile and teratogenic evaluation of potent new analogues of a valproic acid urea derivative in NMRI mice.
Birth defects research. Part B, Developmental and reproductive toxicology 2009;86(5):394-401.
2009: Peter Zannikos; Gerald Novak; Caiping Yao; Tom Verhaeghe; Monique A Franc; Bhavna Solanki; Meir Bialer
Pharmacokinetics of carisbamate (RWJ-333369) in healthy Japanese and Western subjects.
Epilepsia 2009;50(8):1850-9.
2009: Neta Pessah; Meir Bialer; Bogdan Wlodarczyk; Richard H Finnell; Boris Yagen
Alpha-fluoro-2,2,3,3-tetramethylcyclopropanecarboxamide, a novel potent anticonvulsant derivative of a cyclic analogue of valproic acid.
Journal of medicinal chemistry 2009;52(8):2233-42.
2009: Jakob Shimshoni; Emma Dalton; Peter Watson; Yagen Boris; Meir Bialer; Adrian J Harwood
Evaluation of the effects of propylisopropylacetic acid (PIA) on neuronal growth cone morphology.
Neuropharmacology 2009;56(4):831-7.
2009: Meir Bialer; Svein I Johannessen; René H Levy; Emilio Perucca; Torbjörn Tomson; H White
Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX).
Epilepsy research 2009;83(1):1-43.
2008: Akinobu Okada; Yuko Onishi; Boris Yagen; Jakob Avi Shimshoni; Dan Kaufmann; Meir Bialer; Michio Fujiwara
Tetramethylcyclopropyl analogue of the leading antiepileptic drug, valproic acid: evaluation of the teratogenic effects of its amide derivatives in NMRI mice.
Birth defects research. Part A, Clinical and molecular teratology 2008;82(9):610-21.
2008: Jakob Avi Shimshoni; Boris Yagen; Neta Pessah; Bogdan Wlodarczyk; Richard Finnell; Meir Bialer
Anticonvulsant profile and teratogenicity of 3,3-dimethylbutanoylurea: a potential for a second generation drug to valproic acid.
Epilepsia 2008;49(7):1202-12.
2008: Jakob Avi Shimshoni; Meir Bialer; Boris Yagen
Synthesis and anticonvulsant activity of aromatic tetramethylcyclopropanecarboxamide derivatives.
Bioorganic & medicinal chemistry 2008;16(11):6297-305.
2008: Dan Kaufmann; Boris Yagen; Anne Minert; MICHAEL TAL; Marshall Devor; Meir Bialer
Evaluation of the enantioselective antiallodynic and pharmacokinetic profile of propylisopropylacetamide, a chiral isomer of valproic acid amide.
Neuropharmacology 2008;54(4):699-707.
2007: Jakob Shimshoni; Meir Bialer; Bogdan Wlodarczyk; Richard Finnell; Boris Yagen
Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid.
Journal of medicinal chemistry 2007;50(25):6419-27.
2007: Meir Bialer
Generic products of antiepileptic drugs (AEDs): is it an issue?
Epilepsia 2007;48(10):1825-32.
2007: Emilio Perucca; Jacqueline French; Meir Bialer
Development of new antiepileptic drugs: challenges, incentives, and recent advances.
Lancet neurology 2007;6(9):793-804.
2007: Shuchean Chien; Caiping Yao; Annemie Mertens; Tom Verhaeghe; Bhavna Solanki; Dennis R Doose; Gerald Novak; Meir Bialer
An interaction study between the new antiepileptic and CNS drug carisbamate (RWJ-333369) and lamotrigine and valproic acid.
Epilepsia 2007;48(7):1328-38.
2007: Geert Mannens; Jan Hendrickx; C G M Janssen; Shuchean Chien; B Van Hoof; Tom Verhaeghe; Mark Kao; Michael F Kelley; Ivo Goris; M Bockx; B Verreet; Meir Bialer; Willem Meuldermans
The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-) in humans.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(4):554-65.
2007: Christian Elger; Meir Bialer; Joyce A Cramer; Joana Maia; Luis Almeida; Patrício Soares-da-Silva
Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures.
Epilepsia 2007;48(3):497-504.
2007: Jakob Shimshoni; Emma Dalton; A Jenkins; Sara Eyal; K Ewan; Robin S B Williams; N Pessah; Boris Yagen; Adrian J Harwood; Meir Bialer
The effects of central nervous system-active valproic acid constitutional isomers, cyclopropyl analogs, and amide derivatives on neuronal growth cone behavior.
Molecular pharmacology 2007;71(3):884-92.
2007: Meir Bialer
Clinical pharmacology of parenteral use of antiepileptic drugs.
Epilepsia 2007;48 Suppl 8():46-8.
2007: Meir Bialer
Extended-release formulations for the treatment of epilepsy.
CNS drugs 2007;21(9):765-74.
2007: Meir Bialer; Boris Yagen
Valproic Acid: second generation.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2007;4(1):130-7.
2007: Meir Bialer; Svein I Johannessen; Harvey J Kupferberg; René H Levy; Emilio Perucca; Torbjörn Tomson
Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII).
Epilepsy research 2007;73(1):1-52.
2007: Eyal Sobol; Boris Yagen; John G Lamb; H White; Bogdan Wlodarczyk; Richard Finnell; Meir Bialer
Anticonvulsant activity, neural tube defect induction, mutagenicity and pharmacokinetics of a new potent antiepileptic drug, N-methoxy-2,2,3,3-tetramethylcyclopropane carboxamide.
Epilepsy research 2007;73(1):75-84.
2006: Shuchean Chien; Meir Bialer; Bhavna Solanki; Tom Verhaeghe; Dennis R Doose; Gerald Novak; Caiping Yao
Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults.
Epilepsia 2006;47(11):1830-40.
2006: Caiping Yao; Dennis R Doose; Gerald Novak; Meir Bialer
Pharmacokinetics of the new antiepileptic and CNS drug RWJ-333369 following single and multiple dosing to humans.
Epilepsia 2006;47(11):1822-9.
2006: Sara Eyal; John G Lamb; Misty Smith; Boris Yagen; E Fibach; Yoram Altschuler; H White; Meir Bialer
The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver.
British journal of pharmacology 2006;149(3):250-60.
2006: Eyal Sobol; Boris Yagen; H Steve White; Karen S Wilcox; John G Lamb; Orit Pappo; Bogdan Wlodarczyk; Richard Finnell; Meir Bialer
Preclinical evaluation of 2,2,3,3-tetramethylcyclopropanecarbonyl-urea, a novel, second generation to valproic acid, antiepileptic drug.
Neuropharmacology 2006;51(4):933-46.
2006: Akinobu Okada; Yuko Onishi; Yoshinobu Aoki; Boris Yagen; Eyal Sobol; Meir Bialer; Michio Fujiwara
Teratology study of derivatives of tetramethylcyclopropyl amide analogues of valproic acid in mice.
Birth defects research. Part B, Developmental and reproductive toxicology 2006;77(3):227-33.
2006: Meir Bialer
New antiepileptic drugs that are second generation to existing antiepileptic drugs.
Expert opinion on investigational drugs 2006;15(6):637-47.
2005: Meir Bialer
The pharmacokinetics and interactions of new antiepileptic drugs: an overview.
Therapeutic drug monitoring 2005;27(6):722-6.
2005: Ilan Winkler; Eyal Sobol; Boris Yagen; Amir Steinman; Marshall Devor; Meir Bialer
Efficacy of antiepileptic tetramethylcyclopropyl analogues of valproic acid amides in a rat model of neuropathic pain.
Neuropharmacology 2005;49(8):1110-20.
2005: Eyal Sobol; Boris Yagen; Ilan Winkler; Malka Britzi; Dan Gibson; Meir Bialer
Pharmacokinetics and metabolism of a new potent antiepileptic drug, 2,2,3,3-tetramethycyclopropanecarbonylurea, in rats.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(10):1538-46.
2005: Ilan Winkler; Simcha Blotnik; Jakob Shimshoni; Boris Yagen; Marshall Devor; Meir Bialer
Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain.
British journal of pharmacology 2005;146(2):198-208.
2005: Dorit Mimrod; Luigi Maria Specchio; Malka Britzi; Emilio Perucca; Nicola Specchio; Angela La Neve; Stefan Soback; René H Levy; Giuliana Gatti; Dennis R Doose; Bruce E Maryanoff; Meir Bialer
A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy.
Epilepsia 2005;46(7):1046-54.
2005: Sara Eyal; Boris Yagen; Jakob Shimshoni; Meir Bialer
Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives.
Biochemical pharmacology 2005;69(10):1501-8.
2005: Akinobu Okada; Kiyoshi Kushima; Yoshinobu Aoki; Meir Bialer; Michio Fujiwara
Identification of early-responsive genes correlated to valproic acid-induced neural tube defects in mice.
Birth defects research. Part A, Clinical and molecular teratology 2005;73(4):229-38.
2005: Malka Britzi; Emilio Perucca; Stefan Soback; René H Levy; Cinzia Fattore; Francesca Crema; Giuliana Gatti; Dennis R Doose; Bruce E Maryanoff; Meir Bialer
Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine.
Epilepsia 2005;46(3):378-84.
2005: Eyal Sobol; Meir Bialer
Critical analysis of the discrepancy between V(beta) and V(ss) for drugs exhibiting different two-compartment disposition profiles.
Biopharmaceutics & drug disposition 2005;26(2):51-8.
2005: Richard P Shank; Dennis R Doose; Anthony J Streeter; Meir Bialer
Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase.
Epilepsy research 2005;63(2-3):103-12.
2004: Meir Bialer; Roy E Twyman; H White
Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels.
Epilepsy & behavior : E&B 2004;5(6):866-72.
2004: Galit Shaltiel; Alon Shamir; Joseph Shapiro; Daobin Ding; Emma Dalton; Meir Bialer; Adrian J Harwood; Robert H Belmaker; Miriam L. Greenberg; Galila Agam
Valproate decreases inositol biosynthesis.
Biological psychiatry 2004;56(11):868-74.
2004: Akinobu Okada; Yoshinobu Aoki; Kiyoshi Kushima; Hiroshi Kurihara; Meir Bialer; Michio Fujiwara
Polycomb homologs are involved in teratogenicity of valproic acid in mice.
Birth defects research. Part A, Clinical and molecular teratology 2004;70(11):870-9.
2004: Meir Bialer; Svein I Johannessen; Harvey J Kupferberg; René H Levy; Emilio Perucca; Torbjörn Tomson
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII).
Epilepsy research 2004;61(1-3):1-48.
2004: Eyal Sobol; Meir Bialer; Boris Yagen
Tetramethylcyclopropyl analogue of a leading antiepileptic drug, valproic acid. Synthesis and evaluation of anticonvulsant activity of its amide derivatives.
Journal of medicinal chemistry 2004;47(17):4316-26.
2004: Sara Eyal; Boris Yagen; Eyal Sobol; Yoram Altschuler; Miriam Shmuel; Meir Bialer
The activity of antiepileptic drugs as histone deacetylase inhibitors.
Epilepsia 2004;45(7):737-44.
2004: Eyal Sobol; Meir Bialer
The relationships between half-life (t1/2) and mean residence time (MRT) in the two-compartment open body model.
Biopharmaceutics & drug disposition 2004;25(4):157-62.
2004: Eyal Sobol; Meir Bialer
Mathematical comparison between volume of distribution (V) and volume of distribution at steady-state (Vss) utilizing model-independent approach.
Biopharmaceutics & drug disposition 2004;25(2):99-101.
2004: Akinobu Okada; Hiroshi Kurihara; Yoshinobu Aoki; Meir Bialer; Michio Fujiwara
Amidic modification of valproic acid reduces skeletal teratogenicity in mice.
Birth defects research. Part B, Developmental and reproductive toxicology 2004;71(1):47-53.
2004: Meir Bialer; Dennis R Doose; Bindu Murthy; Christopher Curtin; Shean-Sheng Wang; Roy E Twyman; Stefan Schwabe
Pharmacokinetic interactions of topiramate.
Clinical pharmacokinetics 2004;43(12):763-80.
2004: Nina Isoherranen; René H Levy; Boris Yagen; José H Woodhead; H White; Meir Bialer
Metabolism of a new antiepileptic drug, N-methyl-tetramethylcyclopropanecarboxamide, and anticonvulsant activity of its metabolites.
Epilepsy research 2004;58(1):1-12.
2003: Nina Isoherranen; Ofer Spiegelstein; Meir Bialer; Jing Zhang; Michelle Merriweather; Boris Yagen; Michael Roeder; Aleata A Triplett; Volker Schurig; Richard Finnell
Developmental outcome of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric acid, and its enantiomer (R)-alpha-ethyl-oxo-pyrrolidine acetamide in a mouse model of teratogenicity.
Epilepsia 2003;44(10):1280-8.
2003: Nina Isoherranen; H White; Brian D Klein; Michael Roeder; José H Woodhead; Volker Schurig; Boris Yagen; Meir Bialer
Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy.
Pharmaceutical research 2003;20(8):1293-301.
2003: Dennis R Doose; Martin J Brodie; Elaine A Wilson; David W Chadwick; John Oxbury; David J Berry; Stefan Schwabe; Meir Bialer
Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients.
Epilepsia 2003;44(7):917-22.
2003: Nina Isoherranen; Boris Yagen; Ofer Spiegelstein; Richard Finnell; Michelle Merriweather; José H Woodhead; Bogdan Wlodarczyk; H White; Meir Bialer
Anticonvulsant activity, teratogenicity and pharmacokinetics of novel valproyltaurinamide derivatives in mice.
British journal of pharmacology 2003;139(4):755-64.
2003: Svein I Johannessen; Dina Battino; David J Berry; Meir Bialer; Günter Krämer; Torbjörn Tomson; Philip N Patsalos
Therapeutic drug monitoring of the newer antiepileptic drugs.
Therapeutic drug monitoring 2003;25(3):347-63.
2003: Malka Britzi; Stefan Soback; Nina Isoherranen; René H Levy; Emilio Perucca; Dennis R Doose; Bruce E Maryanoff; Meir Bialer
Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay.
Therapeutic drug monitoring 2003;25(3):314-22.
2003: Nina Isoherranen; Boris Yagen; Ofer Spiegelstein; Amir Steinman; Richard Finnell; Meir Bialer
Gas chromatographic determination of novel valproyl taurinamide derivatives in mouse and dog plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;788(1):125-36.
2003: Dennis R Doose; Shean-Sheng Wang; Mukund Padmanabhan; Stefan Schwabe; David Jacobs; Meir Bialer
Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects.
Epilepsia 2003;44(4):540-9.
2003: Nina Isoherranen; Boris Yagen; Meir Bialer
New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet?
Current opinion in neurology 2003;16(2):203-11.
2003: Nina Isoherranen; Boris Yagen; José H Woodhead; Ofer Spiegelstein; Simcha Blotnik; Karen S Wilcox; Richard Finnell; Gregory D Bennett; H White; Meir Bialer
Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents.
British journal of pharmacology 2003;138(4):602-13.
2003: John Williams; Meir Bialer; Svein I Johannessen; Günther Krämer; René Levy; Richard H Mattson; Emilio Perucca; Philip N Patsalos; John F Wilson
Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data.
Epilepsia 2003;44(1):40-5.
2002: Meir Bialer; Svein I Johannessen; Harvey J Kupferberg; René H Levy; P Loiseau; Emilio Perucca
Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI).
Epilepsy research 2002;51(1-2):31-71.
2002: R C Sachdeo; S K Sachdeo; René H Levy; Anthony J Streeter; FE Bishop; K L Kunze; Gary Mather; Lorin K Roskos; Danny D Shen; K E Thummel; William F Trager; Christopher Curtin; Dennis R Doose; LG Gisclon; Meir Bialer
Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients.
Epilepsia 2002;43(7):691-6.
2002: Nina Isoherranen; H White; Richard Finnell; Boris Yagen; José H Woodhead; Gregory D Bennett; Karen S Wilcox; Matthew E Barton; Meir Bialer
Anticonvulsant profile and teratogenicity of N-methyl-tetramethylcyclopropyl carboxamide: a new antiepileptic drug.
Epilepsia 2002;43(2):115-26.
2002: Meir Bialer
New antiepileptic drugs currently in clinical trials: is there a strategy in their development?
Therapeutic drug monitoring 2002;24(1):85-90.
2002: Meir Bialer; Matthew C Walker; Josemir W. Sander
Pros and cons for the development of new antiepileptic drugs.
CNS drugs 2002;16(5):285-9.
2001: M Wasserman; Boris Yagen; Simcha Blotnik; niv papo; Meir Bialer
Stereoselective pharmacokinetic analysis and antiepileptic activity of N-2-hydroxypropyl valpromide, a central nervous system--active chiral valproylamide.
Therapeutic drug monitoring 2001;23(4):414-20.
2001: Nina Isoherranen; José H Woodhead; H White; Meir Bialer
Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug.
Epilepsia 2001;42(7):831-6.
2001: Nina Isoherranen; Boris Yagen; Stefan Soback; Michael Roeder; Volker Schurig; Meir Bialer
Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs.
Epilepsia 2001;42(7):825-30.
2001: Meir Bialer; Svein I Johannessen; Harvey J Kupferberg; René H Levy; P Loiseau; Emilio Perucca
Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V).
Epilepsy research 2001;43(1):11-58.
2000: Ofer Spiegelstein; Boris Yagen; Gregory D Bennett; Richard Finnell; Simcha Blotnik; Meir Bialer
Stereoselective pharmacokinetic analysis of valnoctamide, a CNS-active chiral amide analogue of valproic acid, in dogs, rats, and mice.
Therapeutic drug monitoring 2000;22(5):574-81.
2000: Malka Britzi; Meir Bialer; L Arcavi; A Shachbari; T Kapitulnik; Stefan Soback
Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups.
Therapeutic drug monitoring 2000;22(5):510-6.
2000: A Volosov; Boris Yagen; Meir Bialer
Comparative stereoselective pharmacokinetic analysis of 10-hydroxycarbazepine after oral administration of its individual enantiomers and the racemic mixture to dogs.
Epilepsia 2000;41(9):1107-11.
2000: Nina Isoherranen; Michael Roeder; Stefan Soback; Boris Yagen; Volker Schurig; Meir Bialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion trap mass spectrometric detection.
Journal of chromatography. B, Biomedical sciences and applications 2000;745(2):325-32.
2000: A Volosov; Meir Bialer; S Xiaodong; Emilio Perucca; Amnon C Sintov; Boris Yagen
Simultaneous stereoselective high-performance liquid chromatographic determination of 10-hydroxycarbazepine and its metabolite carbamazepine-10,11-trans-dihydrodiol in human urine.
Journal of chromatography. B, Biomedical sciences and applications 2000;738(2):419-25.
2000: Ofer Spiegelstein; D L Kroetz; René H Levy; Boris Yagen; S I Hurst; M Levi; Abdullah Haj-Yehia; Meir Bialer
Structure activity relationship of human microsomal epoxide hydrolase inhibition by amide and acid analogues of valproic acid.
Pharmaceutical research 2000;17(2):216-21.
1999: A Volosov; S Xiaodong; Emilio Perucca; Boris Yagen; Amnon C Sintov; Meir Bialer
Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects.
Clinical pharmacology and therapeutics 1999;66(6):547-53.
1999: Meir Bialer
Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs.
Journal of controlled release : official journal of the Controlled Release Society 1999;62(1-2):187-92.
1999: Ofer Spiegelstein; Boris Yagen; René H Levy; Richard Finnell; Gregory D Bennett; Michael Roeder; Volker Schurig; Meir Bialer
Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid.
Pharmaceutical research 1999;16(10):1582-8.
1999: Ofer Spiegelstein; Boris Yagen; Meir Bialer
Structure-pharmacokinetic-pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide.
Epilepsia 1999;40(5):545-52.
1999: A Volosov; Amnon C Sintov; Meir Bialer
Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs.
Therapeutic drug monitoring 1999;21(2):219-23.
1999: S Sussan; Arie Dagan; Simcha Blotnik; Meir Bialer
The structural requirements for the design of antiepileptic-glycine derivatives.
Epilepsy research 1999;34(2-3):207-20.
1999: Meir Bialer; Svein I Johannessen; Harvey J Kupferberg; René H Levy; P Loiseau; Emilio Perucca
Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV).
Epilepsy research 1999;34(1):1-41.
1999: Ofer Spiegelstein; Meir Bialer; M Radatz; H Nau; Boris Yagen
Enantioselective synthesis and teratogenicity of propylisopropyl acetamide, a CNS-active chiral amide analogue of valproic acid.
Chirality 1999;11(8):645-50.
1999: A Volosov; Meir Bialer
Use of mean residence time to determine the magnitude of difference between rate constants and to calculate tmax in the Bateman equation.
Biopharmaceutics & drug disposition 1999;20(1):3-9.
1999: S Sussan; Arie Dagan; Meir Bialer
Pharmacokinetic analysis and anticonvulsant activity of glycine and glycinamide derivatives.
Epilepsy research 1999;33(1):11-21.
1998: Meir Bialer; L Arcavi; S Sussan; A Volosov; A Yacobi; D Moros; B Levitt; A Laor
Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine.
Epilepsy research 1998;32(3):371-8.
1998: Meir Bialer; A Yacobi; D Moros; B Levitt; Jean-Marie Houle; M S Munsaka
Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine.
Epilepsia 1998;39(5):513-9.
1998: Simcha Blotnik; F Bergman; Meir Bialer
Disposition of two tetramethylcyclopropane analogues of valpromide in the brain, liver, plasma and urine of rats.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 1998;6(2):93-8.
1998: Meir Bialer; René H Levy; Emilio Perucca
Does carbamazepine have a narrow therapeutic plasma concentration range?
Therapeutic drug monitoring 1998;20(1):56-9.
1997: S Hadad; Meir Bialer
Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide.
Biopharmaceutics & drug disposition 1997;18(7):557-66.
1997: Ofer Spiegelstein; Meir Bialer; Boris Yagen
Isolation of N,N-dialkylated derivatives of valproylglycinamide from dog plasma by active charcoal adsorption and their quantification by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1997;698(1-2):195-200.
1997: Simcha Blotnik; F Bergman; Meir Bialer
The disposition of valproyl glycinamide and valproyl glycine in rats.
Pharmaceutical research 1997;14(7):873-8.
1997: M Levi; Boris Yagen; Meir Bialer
Pharmacokinetics and antiepileptic activity of valproyl hydroxamic acid derivatives.
Pharmaceutical research 1997;14(2):213-7.
1996: Meir Bialer; S I Johannessen; Harvey J Kupferberg; René H Levy; P Loiseau; E Perucca
Progress report on new antiepileptic drugs: a summary of the Third Eilat Conference.
Epilepsy research 1996;25(3):299-319.
1996: Meir Bialer; B Kadry; A Abdul-Hai; A Haj-Yehia; J Sterling; Y Herzig; M Shirvan
Pharmacokinetic and pharmacodynamic analysis of (E)-2-ene valproyl derivatives of glycine and valproyl derivatives of nipecotic acid.
Biopharmaceutics & drug disposition 1996;17(7):565-75.
1996: Emilio Perucca; Meir Bialer
The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine.
Clinical pharmacokinetics 1996;31(1):29-46.
1996: Simcha Blotnik; F Bergman; Meir Bialer
Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats.
Drug metabolism and disposition: the biological fate of chemicals 1996;24(5):560-4.
1996: Meir Bialer; S Hadad; B Kadry; A Abdul-Hai; A Haj-Yehia; J Sterling; Y Herzig; Boris Yagen
Pharmacokinetic analysis and antiepileptic activity of tetra-methylcyclopropane analogues of valpromide.
Pharmaceutical research 1996;13(2):284-9.
1995: J P Stables; Meir Bialer; S I Johannessen; Harvey J Kupferberg; René H Levy; P Loiseau; E Perucca
Progress report on new antiepileptic drugs. A summary of the Second Eilat Conference.
Epilepsy research 1995;22(3):235-46.
1995: Meir Bialer; S Sussan; O Abu Salach; H D Danenberg; J Ben-David; Y Gibor; A Laor
Criteria to assess in vivo performance of sustained release products: application to diltiazem formulations.
Journal of pharmaceutical sciences 1995;84(10):1160-3.
1995: S Hadad; Meir Bialer
Pharmacokinetic analysis and antiepileptic activity of N-valproyl derivatives of GABA and glycine.
Pharmaceutical research 1995;12(6):905-10.
1995: Emil Samara; D Avnir; D Ladkani; Meir Bialer
Pharmacokinetic analysis of diethylcarbonate prodrugs of ibuprofen and naproxen.
Biopharmaceutics & drug disposition 1995;16(3):201-10.
1994: Emilio Perucca; Giuliana Gatti; Giovanna Cipolla; Edoardo Spina; S Barel; Stefan Soback; M Gips; Meir Bialer
Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers.
Clinical pharmacology and therapeutics 1994;56(5):471-6.
1994: O abu Salach; S Hadad; A Haj-Yehia; S Sussan; Meir Bialer
Comparative pharmacokinetic and pharmacodynamic analysis of phthaloyl glycine derivatives with potential antiepileptic activity.
Pharmaceutical research 1994;11(10):1429-34.
1994: S Barel; Boris Yagen; Meir Bialer
Pharmacokinetic profile of conjugated verrucarol urinary metabolites in dogs.
Biopharmaceutics & drug disposition 1994;15(7):609-16.
1994: Meir Bialer; A Haj-Yehia; K Badir; S Hadad
Can we develop improved derivatives of valproic acid?
Pharmacy world & science : PWS 1994;16(1):2-6.
1994: Meir Bialer; S Hadad; Gershon Golomb; S Barel; Emil Samara; O Abu Salach; N Berkman; H D Danenberg; J Ben David; D Caron
Pharmacokinetic analysis of two new sustained-release products of diltiazem designed for twice- and once-daily treatment.
Biopharmaceutics & drug disposition 1994;15(1):45-52.
1993: Meir Bialer
Comparative pharmacokinetics of the newer antiepileptic drugs.
Clinical pharmacokinetics 1993;24(6):441-52.
1993: S Hadad; T B Vree; E van der Kleijn; Meir Bialer
Pharmacokinetic analysis and anticonvulsant activity of two polyesteric prodrugs of valproic acid.
Biopharmaceutics & drug disposition 1993;14(1):51-9.
1993: Boris Yagen; Meir Bialer
Metabolism and pharmacokinetics of T-2 toxin and related trichothecenes.
Drug metabolism reviews 1993;25(3):281-323.
1992: S Hadad; T B Vree; E van der Kleijn; Meir Bialer
Pharmacokinetic analysis of ester prodrugs of valproic acid.
Journal of pharmaceutical sciences 1992;81(10):1047-50.
1992: A Haj-Yehia; S Hadad; Meir Bialer
Pharmacokinetic analysis of the structural requirements for forming "stable" analogues of valpromide.
Pharmaceutical research 1992;9(8):1058-63.
1992: Meir Bialer
Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs. Clinical implications.
Clinical pharmacokinetics 1992;22(1):11-21.
1991: K Badir; A Haj-Yehia; T B Vree; E van der Kleijn; Meir Bialer
Pharmacokinetics and anticonvulsant activity of three monoesteric prodrugs of valproic acid.
Pharmaceutical research 1991;8(6):750-3.
1991: Meir Bialer
Clinical pharmacology of valpromide.
Clinical pharmacokinetics 1991;20(2):114-22.
1990: Emil Samara; Meir Bialer; David Harvey
Pharmacokinetics of urinary metabolites of cannabidiol in the dog.
Biopharmaceutics & drug disposition 1990;11(9):785-95.
1990: A Haj-Yehia; Meir Bialer
Structure-pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity.
Journal of pharmaceutical sciences 1990;79(8):719-24.
1990: S Barel; Boris Yagen; Meir Bialer
Pharmacokinetics of the trichothecene mycotoxin verrucarol in dogs.
Journal of pharmaceutical sciences 1990;79(6):548-51.
1990: Emil Samara; Meir Bialer; H Bar-On; David Harvey
Identification of metabolites of the 1",1"-dimethylheptyl analogue of cannabidiol in rat and dog in vivo.
Xenobiotica; the fate of foreign compounds in biological systems 1990;20(5):447-55.
1990: H Billig; Ehud Ziv; H Bar-On; Meir Bialer
The disposition of valpromide in rats and the isolated perfused rat liver.
Drug metabolism and disposition: the biological fate of chemicals 1990;18(2):238-44.
1990: Emil Samara; Meir Bialer; David Harvey
Identification of glucose conjugates as major urinary metabolites of cannabidiol in the dog.
Xenobiotica; the fate of foreign compounds in biological systems 1990;20(2):177-83.
1990: Meir Bialer; A Haj-Yehia; Nicoletta Barzaghi; F Pisani; E Perucca
Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects.
European journal of clinical pharmacology 1990;38(3):289-91.
1989: A Haj-Yehia; Meir Bialer
Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity.
Pharmaceutical research 1989;6(8):683-9.
1988: Emil Samara; Meir Bialer
Pharmacokinetics of the dimethylheptyl homolog of cannabidiol in dogs.
Drug metabolism and disposition: the biological fate of chemicals 1988;16(6):875-9.
1988: A Haj-Yehia; Meir Bialer
Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs.
Journal of pharmaceutical sciences 1988;77(10):831-4.
1988: Meir Bialer; W H Wu; R D Faulkner; B M Silber; A Yacobi
In vitro protein binding interaction studies involving cefixime.
Biopharmaceutics & drug disposition 1988;9(3):315-20.
1988: Emil Samara; Meir Bialer; Urij Rampampam
Pharmacokinetics of cannabidiol in dogs.
Drug metabolism and disposition: the biological fate of chemicals 1988;16(3):469-72.
1988: Amnon C Sintov; Meir Bialer; Boris Yagen
Pharmacokinetics and protein binding of trichothecene mycotoxins, T-2 toxin and HT-2 toxin, in dogs.
Toxicon : official journal of the International Society on Toxinology 1988;26(2):153-60.
1987: Z Hussein; Meir Bialer; Michael Friedman; I Raz
Pharmacokinetic analysis of sustained-release dosage forms of theophylline in humans: comparison of single and multiple dose studies.
Biopharmaceutics & drug disposition 1987;8(5):427-35.
1987: Amnon C Sintov; Meir Bialer; Boris Yagen
Pharmacokinetics of T-2 tetraol, a urinary metabolite of the trichothecene mycotoxin, T-2 toxin, in dog.
Xenobiotica; the fate of foreign compounds in biological systems 1987;17(8):941-50.
1987: Meir Bialer; W H Wu; Z M Look; B M Silber; A Yacobi
Pharmacokinetics of cefixime after oral and intravenous doses in dogs: bioavailability assessment for a drug showing nonlinear serum protein binding.
Research communications in chemical pathology and pharmacology 1987;56(1):21-32.
1987: Meir Bialer; V K Batra; J A Morrison; B M Silber; Z M Look; A Yacobi
Dose-dependent pharmacokinetics of a new oral cephalosporin, cefixime, in the dog.
Pharmaceutical research 1987;4(1):33-7.
1986: Meir Bialer; Z M Look; B M Silber; A Yacobi
The relationship between drug input and mean residence time in the body.
Biopharmaceutics & drug disposition 1986;7(6):577-83.
1986: Boris Yagen; Amnon C Sintov; Meir Bialer
New, sensitive thin-layer chromatographic-high-performance liquid chromatographic method for detection of trichothecene mycotoxins.
Journal of chromatography 1986;356(1):195-201.
1986: Amnon C Sintov; Meir Bialer; Boris Yagen
Pharmacokinetics of T-2 toxin and its metabolite HT-2 toxin, after intravenous administration in dogs.
Drug metabolism and disposition: the biological fate of chemicals 1986;14(2):250-4.
1985: Boris Yagen; Meir Bialer; Amnon C Sintov
Gas chromatographic assay with pharmacokinetic applications for monitoring T-2 and HT-2 toxins in plasma.
Journal of chromatography 1985;343(1):67-75.